GlassScriptPhysician profile
Barry F Faust
NPI 1366673626
$3,763.24
in general payments reported to CMS, 2019-2025
27 companies · $1,337 in 2025
The $1,337 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $976 · 2020: $394 · 2021: $453 · 2022: $38.08 · 2023: $504 · 2024: $60.01 · 2025: $1,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,024 · Travel and Lodging: $877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,023.65 |
| Travel and Lodging | $877.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $983.94 | 2025 | Mild Device Kit |
| Medtronic, INC. | $435.42 | 2021-2023 | Unid_pass |
| Medtronic USA, INC. | $412.77 | 2019-2020 | |
| Spr Therapeutics, INC | $241.16 | 2023 | Sprint Pns System |
| Pfizer INC. | $201.57 | 2019-2021 | |
| Kerecis Limited | $174.57 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Scilex Pharmaceuticals INC. | $140.95 | 2019-2020 | |
| Derma Sciences, INC. | $136.17 | 2019 | |
| Foundation Fusion Solutions, LLC | $136.07 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $128.89 | 2019-2020 | |
| Horizon Therapeutics Plc | $125.00 | 2019 | |
| Boston Scientific Corporation | $119.20 | 2020-2021 | |
| Vertex Pharmaceuticals Incorporated | $111.74 | 2025 | |
| Abbott Laboratories | $107.74 | 2020-2022 | |
| Mdd US Operations, LLC | $43.73 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spinal Simplicity, LLC | $37.99 | 2024 | Ha Minuteman G3-R |
| Daiichi Sankyo INC. | $29.33 | 2019 | |
| Novo Nordisk INC | $26.39 | 2025 | Wegovy |
| Biodelivery Sciences International, INC. | $23.68 | 2019 | |
| Itamar Medical INC | $22.61 | 2023 | Watchpatone |
| Nalu Medical, INC. | $22.02 | 2024 | Nalu Neurostimulation System |
| Biotronik Nro, INC. | $21.71 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $18.34 | 2023 | Iovera |
| Lilly USA, LLC | $18.30 | 2025 | Mounjaro |
| Stimwave Technologies Incorporated | $17.00 | 2020 | |
| Assertio Therapeutics, INC. | $16.22 | 2019 | |
| Forte Bio-Pharma LLC | $10.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Faust listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.